peoplePerson
Robert D. Schreiber
Proposed cancer immunoediting and showed neoantigens are the targets of checkpoint immunotherapy.
Immunologist who established the three-phase immunoediting model and demonstrated that mutant neoantigens mediate rejection of checkpoint-treated tumours.
Role
Andrew M. and Jane M. Bursky Distinguished Professor; Director, Bursky Center for Human Immunology and Immunotherapy Programs
Institution
Specialisms
Cancer immunoeditingNeoantigensInterferon-gamma
Profiles
| Title | Journal | Year |
|---|---|---|
| Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens | Nature | 2014 |
Pages like this
not linked directly; found by shared links- PersonMalachi Griffith
Shares Siteman Cancer Center, Washington University, Neoantigen.
- PersonKellie N. Smith
Shares Neoantigen, Immune checkpoint inhibitors.
- PersonTimothy A. Chan
Shares Neoantigen, Immune checkpoint inhibitors.
- IdeaWhat makes a neoantigen actually immunogenic?
Shares Siteman Cancer Center, Washington University, Neoantigen.
- InstitutionLeiden University Medical Center
Shares Neoantigen, Immune checkpoint inhibitors.
- InstitutionLausanne University Hospital (CHUV) / Ludwig Institute Lausanne
Shares Neoantigen, Immune checkpoint inhibitors.
- IdeaCheck whether a tumour can still show itself to the immune system
Shares Neoantigen, Immune checkpoint inhibitors.
- Key paperLe 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ
Shares Neoantigen, Immune checkpoint inhibitors.